Topical Retinoids and Pregnancy: Discontinuation Timing
Topical retinoids do not need to be stopped before attempting pregnancy, though discontinuation is often recommended as a precautionary measure despite reassuring safety data.
Evidence-Based Recommendation
The most recent and highest quality evidence shows no increased risk of major congenital malformations (MCM) or spontaneous abortion with first-trimester topical retinoid exposure 1, 2. A 2025 Nordic cohort study of nearly 4 million pregnancies found that among 2,172 infants exposed to topical retinoids in the first trimester, 3.3% had MCM compared to 3.0% in unexposed infants (adjusted RR 1.1,95% CI 0.87-1.38) 1. A 2026 meta-analysis of 8 studies encompassing over 3.6 million pregnancies confirmed these findings with pooled RR of 0.83 (95% CI 0.64-1.07) for MCM and 0.99 (95% CI 0.68-1.43) for spontaneous abortion 2.
Clinical Context and Nuance
The traditional precautionary approach stems from extrapolation of systemic retinoid teratogenicity, not from actual topical retinoid data. Systemic retinoids like isotretinoin and acitretin are highly teratogenic and require strict pregnancy prevention 3, 4, 5. However, topical formulations have minimal systemic absorption and third-generation topical retinoids (adapalene, tazarotene) have structural modifications that limit off-target activity 6.
Guideline Recommendations vs. Current Evidence
Guidelines remain conservative despite reassuring data:
- The 2024 AAD acne guidelines state "pregnancy prevention is mandatory" for isotretinoin but do not specify discontinuation timing for topical retinoids 7
- The 2021 AAD-NPF psoriasis guidelines recommend obtaining a negative pregnancy test 2 weeks before starting tazarotene and counseling women to discontinue if pregnancy occurs 8
- The 2010 British guidelines on acitretin (oral retinoid) recommend 3 years of contraception after stopping due to prolonged elimination 5
However, these recommendations were written before the large 2025 Nordic study and 2026 meta-analysis demonstrating safety.
Practical Algorithm
If Continuing Topical Retinoids:
- No mandatory washout period is required based on current evidence 1, 2
- Counsel patients about the reassuring safety data while acknowledging the precautionary stance in package inserts
- Document shared decision-making in the medical record
If Discontinuing (Conservative Approach):
- Stop immediately upon pregnancy recognition or
- Stop when actively attempting conception (no specific washout period needed given minimal systemic absorption)
- Unlike oral retinoids, topical formulations do not require extended washout periods
Key Distinction from Oral Retinoids:
- Oral isotretinoin: Requires 1 month washout and strict pregnancy prevention 4, 9
- Oral acitretin: Requires 3 years of contraception after stopping due to conversion to etretinate with alcohol 4, 5
- Topical retinoids: No evidence-based washout period required 1, 2
Important Caveats
The increased rate of elective terminations (3.4-fold) in exposed pregnancies reflects patient and provider anxiety rather than actual risk 10. This highlights the importance of accurate counseling to prevent unnecessary pregnancy terminations.
If inadvertent first-trimester exposure occurs, reassure patients that available data show no increased risk of retinoid embryopathy or major malformations 1, 2, 6, 10. No cases of characteristic retinoid embryopathy have been reported with topical use 10.
The dramatic 3.3-fold increase in topical retinoid use among reproductive-age women (from 8.7 to 28.5 per 1000 between 2006-2024) makes evidence-based counseling increasingly important 1.